TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3300423
Drug: Subarachnoid lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subarachnoid lidocaine 1 mg/kg plus salmon calcitonin (sCT) 100 IU
Study: 28540394
Drug: Two-year oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-year oral health programme
Study: 26856306
Drug: Simple postal
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple postal intervention highlighting the importance of maintaining asthma medication
Study: 24499161
Drug: No-treatment control
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-treatment control residence
Study: 15708844
Drug: 900 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 900 mg/day hypericum extract WS 5570 three times a day for six weeks
Study: 15708844
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg paroxetine once a day for six weeks
Study: 12408204
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment group including a couples intervention
Study: 12408204
Drug: Standard behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard behavioral treatment group
Study: 7657029
Drug: Hyperinsulinemic euglycemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperinsulinemic euglycemic clamp (plasma insulin concentration 586 +/- 9.7 pmol/l) for 13 hours
Study: 7657029
Drug: Saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infusion for 13 hours (control)
Study: 2652546
Drug: CyA and
Normalized name: CyA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CyA and steroids (Group III)
Study: 791585
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/day) plus placebo
Study: 791585
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg/day) plus proglumide (900 mg/day)
Study: 28677982
Drug: Triglyceride (TG)
Normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triglyceride (TG) in combination with waist circumference (WC)
Study: 28677982
Drug: Weekly Cola
Normalized name: cola extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly Cola consumption in women
Study: 24617605
Drug: Pitavastatin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin (1 mg) with rifampicin (600 mg)
Study: 24617605
Drug: Rosuvastatin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosuvastatin (5 mg) with rifampicin (600 mg)
Study: 22733794
Drug: Self-managed computer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-managed computer treatment with volunteer support
Study: 15697102
Drug: Combined oral
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined oral contraceptive containing 30 microg ethinylestradiol and 150 microg levonorgestrel
Study: 16158750
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (15 mg/day, titrated to a maximum of 45 mg)
Study: 16158750
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride (30 mg and then 45 mg/day for 3 patients)
Study: 1646290
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg sumatriptan
Study: 1646290
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg sumatriptan
Study: 1653137
Drug: All active
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All active treatment groups (100 mg, 200 mg, 300 mg sumatriptan)
Study: 1653137
Drug: Sumatriptan (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan (all doses)
Study: 30552060
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of tyrosine with cathodal tDCS
Study: 18521048
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh (BC) treatment for 12 weeks at a standard dose (Remifemin, 40 mg/day)
Study: 18521048
Drug: Black cohosh
Normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black cohosh treatment
Study: 10519894
Drug: Transplantation (myeloablative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplantation (myeloablative chemotherapy, total-body irradiation, and transplantation of autologous bone marrow)
Study: 10519894
Drug: Continuation chemotherapy
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuation chemotherapy (intensive chemotherapy alone)
Study: 31442203
Drug: Achillea wilhelmsii
Normalized name: Achillea millefolium oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Achillea wilhelmsii C. Koch capsules
Study: 23739785
Drug: 1.23% APF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.23% APF gel
Study: 27749616
Drug: Ultrasound-guided steroid
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided steroid injection (40 mg of methylprednisolone)
Study: 23811617
Drug: Blind steroid
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blind steroid injection (40 mg of methylprednisolone)
Study: 17086095
Drug: Isosorbide-5-mononitrate (IS-5-MN),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isosorbide-5-mononitrate (IS-5-MN), 60 mg orally, once daily for 11 months
Study: 9159453
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor binding protein 1 (IGFBP-1)
Study: 31616139
Drug: Fortasyn Connect
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fortasyn Connect (daily medical food containing docosahexaenoic acid, eicosapentaenoic acid, uridine monophosphate, choline, phospholipids, selenium, folic acid, vitamins B12, B6, C, and E)
Study: 26112273
Drug: Transdermal fentanyl
Normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Transdermal fentanyl patch (TFP) 12.5 μg/h
Study: 26112273
Drug: Non-steroid anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroid anti-inflammatory drugs (NSAID)
Study: 24108510
Drug: Simvastatin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (60 mg)
Study: 11016522
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment in community mental health centres
Study: 9686071
Drug: Interscalene brachial
Normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interscalene brachial plexus block (IBPB) with sedation (midazolam: 1‐3 mg)
Study: 2943191
Drug: Midazolam 0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.07 mg/kg intramuscularly
Study: 16792771
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of salicylic acid (twice daily then once daily)
Study: 15119640
Drug: Graduate-measured volume
Approvals — FDA: no, EMA: no, PMDA: no
Description: Graduate-measured volume using a 2-L graduated cylinder
Study: 9517371
Drug: nadolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: nadolol (40 mg)
Study: 7527100
Drug: Trandolapril 0.5
Normalized name: trandolapril 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 0.5 mg
Study: 7527105
Drug: Trandolapril 1
Normalized name: trandolapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 1 mg
Study: 2685740
Drug: Extracorporeal membrane
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extracorporeal membrane oxygenation (ECMO) therapy
Study: 29111629
Drug: Muay Thai
Normalized name: Thai galangal extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muay Thai training twice a week (G2X)
Study: 20844186
Drug: Increased leucine
Normalized name: Leucine
DrugBank: Leucine (DB00149)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Increased leucine concentration (LEU; 3.5 g leucine)
Study: 20844186
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (CTRL; 1.8 g leucine)
Study: 29799676
Drug: Rucaparib 40-500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 40-500 mg QD
Study: 29799676
Drug: Rucaparib 240-840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 240-840 mg BID
Study: 29799676
Drug: Rucaparib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 600 mg BID (phase 2)
Study: 29799676
Drug: Rucaparib 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 40 mg (single dose)
Study: 29799676
Drug: Rucaparib 300
Normalized name: rucaparib 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rucaparib 300 mg (single dose)
Study: 25607702
Drug: ALA-PDT (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (2 treatments)
Study: 25607702
Drug: ALA-PDT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (1 treatment) + ingenol mebutate 0.015% gel (3 days)
Study: 25607702
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate 0.015% gel alone
Study: 25607702
Drug: ALA-PDT (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALA-PDT (1 treatment) + ingenol mebutate gel (3 days)
Study: 25607702
Drug: ingenol mebutate
Normalized name: Ingenol Mebutate
DrugBank: Ingenol mebutate (DB05013)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ingenol mebutate gel alone
Study: 23826844
Drug: ER tolterodine
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: ER tolterodine 4 mg
Study: 20642044
Drug: Ice gel
Normalized name: Ice Gel
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice gel
Study: 18521900
Drug: Selective leukocytapheresis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective leukocytapheresis (5 sessions, once weekly)
Study: 18521900
Drug: Unchanged maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unchanged maintenance treatment (Control)
Study: 12799510
Drug: Control vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control vaccine (conjugate meningococcus C vaccine)
Study: 11059992
Drug: Risperidone (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (single dose)
Study: 11059992
Drug: Risperidone (six
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risperidone (six weeks treatment)
Study: 3745103
Drug: Nifedipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (20 mg, sublingual administration)
Study: 24879495
Drug: THC 29
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 29 mg
Study: 24879495
Drug: THC 49
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 49 mg
Study: 24879495
Drug: THC 69
Normalized name: THC
DrugBank: Dronabinol (DB00470)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: THC 69 mg
Study: 23039319
Drug: High-dose amoxicillin/clavulanic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose amoxicillin/clavulanic acid (80 mg/kg/day for 10 days)
Study: 23039319
Drug: Cefdinir (14
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefdinir (14 mg/kg/day for 5 days)
Study: 15994038
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris extract (20 mg/kg body weight per day)
Study: 15994038
Drug: Tribulus terrestris
Normalized name: TRIBULUS TERRESTRIS
DrugBank: Tribulus terrestris (DB14358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tribulus terrestris extract (10 mg/kg body weight per day)
Study: 31463821
Drug: Sublingual SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual SAM 10 mg
Study: 31463821
Drug: Oral SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SAM 10 mg
Study: 31463821
Drug: Intravenous SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous SAM
Study: 31463821
Drug: Oral SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SAM 10 mg under fed conditions (cohort 1)
Study: 31463821
Drug: Oral SAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral SAM 10 mg for young and elderly participants
Study: 18562974
Drug: Prescriptions to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions to walk 5-7 days/week
Study: 18562974
Drug: Prescriptions to
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescriptions to walk at moderate intensity
Study: 14499422
Drug: Controlled-release oxycodone
Normalized name: oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Controlled-release oxycodone (10 mg to 40 mg q12h)
Study: 11273538
Drug: antacid-acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: antacid-acid
Study: 11273538
Drug: acid-antacid
Normalized name: calcium carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: acid-antacid
Study: 11273538
Drug: antacid-antacid (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: antacid-antacid (control)
Study: 9089851
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg of nalbuphine intravenously
Study: 9089851
Drug: 0.0, 0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.0, 0.3, 0.6, 0.9, 1.2, and 1.5 mg/kg of 2‐chloroprocaine
Study: 7693504
Drug: terfenadine, 180
Approvals — FDA: no, EMA: no, PMDA: no
Description: terfenadine, 180 mg, by mouth
Study: 7693504
Drug: ipratropium bromide,
Normalized name: Ipratropium Bromide, compounding powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: ipratropium bromide, 0.5 mg, nebulized
Study: 7693504
Drug: both active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: both active drugs together (terfenadine and ipratropium bromide)
Study: 7693504
Drug: placebo preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo preparations (by mouth and by nebulizer)
Study: 3536171
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose sublingual therapy with house dust mite
Study: 15755834
Drug: Wheat products
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat products fortified with 0 mg Zn (group Zn-0)
Study: 15755834
Drug: Wheat products
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat products fortified with 3 mg Zn (group Zn-3)
Study: 15755834
Drug: Wheat products
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat products fortified with 9 mg Zn (group Zn-9)
Study: 12585143
Drug: Wuzi Yanzong
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wuzi Yanzong Pill (WZYZP)
Study: 2328178
Drug: Edrophonium 0.1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Edrophonium 0.1, 0.2, 0.4 or 1 mg kg‐1
Study: 20530934
Drug: L-carnitine supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-carnitine supplementation (2 g/day)
Study: 9643568
Drug: Anthracycline‐AraC intensive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline‐AraC intensive chemotherapy
Study: 9643568
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose AraC
Study: 3063328
Drug: Two-antibody depleted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-antibody depleted grafts (T10B9 and T12A10)
Study: 3063328
Drug: One-antibody depleted
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-antibody depleted grafts (T10B9)
Study: 30307720
Drug: Mini dental
Normalized name: oxymetazoline hydrochloride Nasal Solution [Iliadin Mini]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini dental implants
Study: 27649676
Drug: BIFICO treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIFICO treatment (oral admission)
Study: 27649676
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (primary disease treatment alone)
Study: 15983319
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy (simvastatin 20 mg daily after cerivastatin 0.4 mg daily)
Study: 10699602
Drug: Intramuscular injections
Normalized name: intramuscular immunoglobulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injections of 240 mg polyestradiol phosphate (PEP) every second week for the first 8 weeks followed by a maintenance dose of 240 mg every month (n = 458)
Study: 10699602
Drug: Total androgen
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total androgen ablation (TAA) via bilateral orchiectomy or triptorelin 3.75 mg every month combined with flutamide 250 mg three times daily (n = 457)
Study: 9382545
Drug: Continuous hepatic
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous hepatic arterial infusion of 5‐FU (360 mg/m2/day x 5 days/week x 4 weeks)
Study: 9382545
Drug: Continuous intravenous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous intravenous infusion of 5‐FU (360 mg/m2/day x 2 weeks)
Study: 31492651
Drug: ozanimod 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozanimod 1.0 mg
Study: 31492651
Drug: ozanimod 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ozanimod 0.5 mg
Study: 23840043
Drug: HIV-1 PENNVAX®-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) with electroporation
Study: 23840043
Drug: HIV-1 PENNVAX®-B
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV-1 PENNVAX®-B DNA vaccine (PV) plus interleukin 12 (IL-12) without electroporation
Study: 9225876
Drug: S-adenosyl-L-methionine (SAMe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-adenosyl-L-methionine (SAMe) 600 mg i.v. daily for 10 days
Study: 3624669
Drug: Active pyridostigmine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pyridostigmine (180 mg orally every 12 hours)
Study: 23532240
Drug: EDTA chelation
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDTA chelation (3 g of disodium EDTA, 7 g of ascorbate, B vitamins, electrolytes, procaine, and heparin) administered via 40 infusions of a 500-mL solution over 30 weeks (weekly for 30 weeks, then 10 infusions 2 to 8 weeks apart)
Study: 23532240
Drug: Placebo (500-mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (500-mL solution) administered in the same regimen as the EDTA group
Study: 18761646
Drug: Metformin (MET),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (MET), n = 15, dose: 1500 mg daily
Study: 17405254
Drug: Combination IGF‐I/GH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination IGF‐I/GH therapy
Study: 17405254
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (normal saline solution)
Study: 10767775
Drug: Denacen (test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Denacen (test formulation)
Study: 10767775
Drug: Calcort (reference
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcort (reference formulation)
Study: 1678757
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone injection pen
Study: 30171664
Drug: Immediate intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intensive treatment (eyedrops containing drugs from three different classes combined with 360° laser trabeculoplasty)
Study: 30171664
Drug: Commonly recommended
Normalized name: Common carp
DrugBank: Common carp (DB10614)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Commonly recommended stepped regimen (drug monotherapy in accordance with common glaucoma guidelines)
Study: 22552037
Drug: DHA-enriched fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA-enriched fish oil (800 mg/d)
Study: 22552037
Drug: Vegetable oil
Normalized name: Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vegetable oil capsules without DHA
Study: 18418808
Drug: Taper period
Normalized name: caper berry extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taper period after both training types
Study: 2389061
Drug: Controlled release
Normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled release vaginal polymer pessary containing 10 mg prostaglandin E2 (PGE2), designed to release 0.6 mg per hour in vivo
Study: 1015181
Drug: Subcutaneous heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous heparin (5,000 U) administered 2 hours before surgery and every 8 hours for 6 days
Study: 7073148
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no heparin treatment)
Study: 30593689
Drug: BRP0.5: basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRP0.5: basal diet + 0.25 g BPO + 0.25 g RPO/kg diet
Study: 30593689
Drug: BRP1.0: basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRP1.0: basal diet + 0.50 g BPO + 0.50 g RPO/kg diet
Study: 30593689
Drug: BRP1.5: basal
Approvals — FDA: no, EMA: no, PMDA: no
Description: BRP1.5: basal diet + 0.75 g BPO + 0.75 g RPO/kg diet
Study: 25224814
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy (CRT) with weekly cisplatin (30 mg/m²) and the same RT dose (66-70 Gy/2 Gy fraction/5 fractions weekly)
Study: 25224814
Drug: Conventional radiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional radiotherapy (RT) (66-70 Gy/2 Gy fraction/5 fractions weekly)
Study: 25224814
Drug: Accelerated radiotherapy
Normalized name: Serum prothrombin conversion accelerator
DrugBank: Coagulation factor VII human (DB13150)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Accelerated radiotherapy (RT) (66-70 Gy/2 Gy fraction/6 fractions weekly)
Study: 24484450
Drug: Salovum® (16
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salovum® (16 grams initially, followed by 8 g every 5 hours until recovery)
Study: 24484450
Drug: Placebo (ordinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (ordinary egg yolk mixed in oral rehydration salts)
Study: 12966253
Drug: Treatment (not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment (not specified in the abstract)
Study: 6404595
Drug: Low-dose combined
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combined oral contraceptive (ethinyl estradiol 0.03 mg and levonorgestrel 0.15 mg)